Nature Medicine, Published online: 06 June 2025; doi:10.1038/s41591-025-03733-4
Recognizing ovarian aging as a formal diagnosis — akin to how the field of obstetrics adopted the concept of ‘advanced maternal age’ — would transform reproductive medicine, public health and research into women’s health.- June 6, 2025
- 0 Comment
Attendees can learn about Bascom’s portfolio of clean label and organic maple syrup solutions and discover more about maple’s versatility, along with its many nutritional and functional benefits, during the Expo being held at McCormick Place in Chicago, July 14–16.
- June 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 June 2025; doi:10.1038/s41591-025-03730-7
A 50 microRNA-based dynamic risk score for stratifying individuals with and without type 1 diabetes was developed using samples obtained from multicenter and multiethnic cohorts.- June 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 June 2025; doi:10.1038/s41591-025-03699-3
In this genomic analysis of peripheral blood samples of the phase 3 CheckMate-067 trial of ipilimumab (IPI) versus nivolumab (NIVO) versus ipilimumab and nivolumab (IPI-NIVO) in melanoma, the status of certain mitochondrial haplogroups in patients was associated therapeutic resistance to NIVO or IPI-NIVO, a finding validated in an independent cohort.- June 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 June 2025; doi:10.1038/s41591-025-03759-8
Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived — a shift that begins with the language used to name and describe them.- June 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 June 2025; doi:10.1038/s41591-025-03795-4
The newly launched PREPARED Code presents a much-needed framework to ensure that research during pandemics is trustworthy and accessible to all.- June 5, 2025
- 0 Comment
- June 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03719-2
Deep phenotyping of responses to carbohydrate meals and mitigators revealed interindividual differences in postprandial glycemic responses that reflect underlying metabolic physiology, such as insulin resistance and beta cell dysfunction.- June 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03725-4
The final analysis from the phase 3 IMpassion031 trial shows that adding atezolizumab to chemotherapy for stage II/III triple-negative breast cancer is associated with favorable long-term outcomes, with circulating tumor DNA clearance correlating with therapy response.- June 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03734-3
A single-arm phase 2 trial in patients with mostly PD-L1-negative advanced triple-negative breast cancer shows that treatment with the anti-PD-L1 agent atezolizumab, paclitaxel and the anti-VEGF agent bevacizumab prolongs progression-free survival.- June 4, 2025
- 0 Comment
